Il-17 Levels in Intrahepatic Cholestasis of Pregnancy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01898832|
Recruitment Status : Unknown
Verified July 2013 by Ayse Kirbas, Zekai Tahir Burak Maternity and Teaching Hospital.
Recruitment status was: Recruiting
First Posted : July 12, 2013
Last Update Posted : March 18, 2014
|Condition or disease|
|Intrahepatic Cholestasis of Pregnancy|
Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent pregnancy-specific liver disease. It occurs mainly in the second or third trimester of pregnancy. It typically resolves after delivery spontaneously but it is associated with an increased risk of adverse fetal outcomes.
The cause of ICP is heterogeneous, pathophysiology is poorly understood and therapies have been empiric. Genetic predispositions, environmental influences, dietary factors and hormonal influences have been studied and cited in the literature.
Comparing with placebo, ursodeoxycholic acid (UDCA) has been shown improvement in treatment of pruritus in previous studies. S-adenosylmethionine, guar gum, activated charcoal, dexamethasone, cholestyramine, etc. are not effective in the treatment of symptoms.
CD4+ T cells are an essential regulators of immune responses and inflammatory diseases. They are also called chief of orchestra cells of immune system. The balance between T helper-(Th)1, Th-2 and Th-17 cells and their cytokinergic interaction are crucial for the response of the organism. Th17 and its specific cytokine IL-17 are responsible for pathogenesis of autoimmune diseases as autoimmune uveitis, experimental autoimmune encephalomyelitis in animal models and potentially also in human autoimmune diseases such as multiple sclerosis, Crohn's disease, rheumatoid arthritis, psoriasis, primary biliary cirrhosis. Recently, IL-17 targeted therapies (secukinumab, ixekizumab and brodalumab) are being studied in Phase III clinical trials to evaluate their overall efficacy and safety for certain autoimmune diseases.
Th-17 levels have been investigated in normal and abnormal pregnancies and results were incompatible with each other. Some researchers have said that the level of IL-17 increased during pregnancy but the others not.
Low serum IL-17 is associated with premature birth. Up-regulation of the IL-17 is associated with preeclampsia.
K. Harada et all. (2009) demonstrated that IL-17-positive cells are associated with the chronic inflammation of bile ducts in primary biliary cirrhosis(PBC). Also, some authors demonstrated that Th-17-related cytokines were increased significantly in patients with PBC.
Maho Ichikawa et all. presented a case of male newborn infant who showed progressive severe cholestasis with selectively high Levels of Serum IL- 17.
Based on all this information, we decided to investigate maternal and fetal serum IL-17 levels of pregnants with ICP and the effects of UDCA therapy on it and find out if Th-17 cells have a role in progress of ICP.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Target Follow-Up Duration:||12 Months|
|Official Title:||to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||July 2014|
- il-17 levels [ Time Frame: 12 months ]
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01898832
|Contact: ayse kirbas, md||+ 90 533 646 92 email@example.com|
|Contact: ayse kirbas||+90 312-306-5000|
|Zekai Tahir Burak||Recruiting|
|Ankara, Turkey, 06080|
|Contact: ayse kirbas, md +90 533 646 92 13 firstname.lastname@example.org|
|Principal Investigator: ayse kirbas, md|
|Principal Investigator:||ayse kirbas, md||Zekai Tahir Burak Women's Health Research and Education Hospital|